Roivant Sciences reported a net loss of $166 million for the quarter ended September 30 2025, a loss per share of $0.17, and a consolidated cash balance of $4.4 billion. Revenue for the period was $1.57 million, falling sharply from $4.48 million in the same quarter a year earlier and missing the consensus estimate of $5.6 million by roughly 70%.
Continue reading for full analysis...